Phase 2b TARGET Trial Results Show Improved Survival in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide

- Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid -

- Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of Death in Pre-Defined Adenocarcinoma Patient Subgroup -

- Conference Call/Webcast at 8:30 a.m. EDT Monday, Sept. 29 -

WEST LAFAYETTE, Ind., Sept. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), today announced that the small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel extended overall survival (OS) for patients with folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC) compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress (ESMO), by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27 percent reduction in risk of the disease worsening or death (HR=0.73, p=0.0899, one-sided test), and a 30 percent reduction in the risk of death (HR=0.70, p=0.1018) compared to docetaxel monotherapy. Stratified analysis, which adjusts for pre-defined patient characteristics in the trial, reflect a 49 percent reduction in the risk of death in patients with adenocarcinoma (HR=0.51, p=0.0147). These data include approximately 78 percent of the targeted number of events in the overall survival analysis. Overall survival in all patients, including those with squamous disease, reflect a 12 percent reduction in the risk of death (HR=0.88, p=0.2874) or 25 percent reduction when stratified (HR=0.75, p=0.1066). The primary endpoint of the study, as presented previously, showed that risk of disease worsening or death (progression-free survival, or PFS) was reduced by 25 percent for patients who received vintafolide plus docetaxel (HR=0.75, p=0.0696).

"We were pleased to see favorable results in the adenocarcinoma subgroup, where intensity of FR expression is approximately 20-fold higher than in squamous cell disease," said Ron Ellis, president and CEO at Endocyte. "We are currently evaluating the development plan for vintafolide in NSCLC in this patient population to determine if we will advance vintafolide quickly to a phase 3 trial after the OS data is fully mature. In the meantime, we continue to progress in the phase 1 studies of two other SMDCs. Our financial strength enables us to explore moving forward with more than one of our wholly-owned pipeline agents in select indications should it be the most beneficial path for the company and patients."

Dr. Rohit Lal said, "These results are very promising for patients receiving second-line treatment for this challenging disease. The folate receptor is a promising target, particularly in NSCLC, where the majority of patients are positive for this receptor. In particular, the consistency of results among patients with adenocarcinoma, including improved tumor response, delayed disease progression, and extended overall survival, support continued study of vintafolide in this patient population."

The study enrolled and treated 199 patients whose target tumors were all positive for the folate receptor, as determined with the companion imaging agent etarfolatide. Patients were randomized between three arms: vintafolide monotherapy, a combination of vintafolide and docetaxel, and docetaxel monotherapy. The independent data safety monitoring board determined before the completion of the trial that the vintafolide monotherapy arm was not likely to demonstrate increased benefit in the delay of disease progression compared to docetaxel alone.

Patients with recurrent folate-receptor positive adenocarcinoma NSCLC
    Vintafolide +  
    Docetaxel Docetaxel
  Comparison* (N=43) (N=49)
Overall response rate 6.6% difference 20.90% 14.30%
Median progression free survival 1.2 month difference 4.2 months 3.0 months
Unstratified analysis HR=0.73, p=0.0899    
Stratified analysis HR=0.68, p=0.0732    
Median overall survival 5.9 month difference, 12.5 months 6.6 months
Unstratified analysis HR=0.70, p=0.1018    
Stratified analysis HR=0.51, p=0.0147    
* One-side p-value

The most common (>5 percent incidence) Grade 3 or higher adverse events occurring more frequently in the vintafolide plus docetaxel arm compared to docetaxel monotherapy were neutropenia (72 percent vs. 55 percent), febrile neutropenia (14 percent vs. 6 percent), sepsis/neutropenic sepsis (6 percent vs. 2 percent), and peripheral neuropathy (9 percent vs. 0 percent).

Endocyte's management will host a conference call and webcast Monday to discuss the TARGET trial results:

Date: Sept. 29, 2014
Time: 8:30 a.m. EDT
Dial: (877) 845-0711 (US/Canada) or (760) 298-5081 (International) 

Webcast information can be accessed under "Events & Presentations" in the Investors & News section of Endocyte's website at www.endocyte.com.    ;

About the TARGET trial

TARGET is an international, multicenter, open-label Phase 2b study designed to evaluate vintafolide in patients with stage IIIb or IV NSCLC with all lesions positive for the folate receptor [FR(100%)] as determined by the investigational companion imaging agent etarfolatide (EC20) and who have failed one prior chemotherapy (ClinicalTrials.gov Identifier: NCT01577654 ). The trial was conducted in 199 patients. The primary endpoint was an improvement in PFS and secondary endpoints include the comparison of overall response rate, disease control rate, duration of response, duration of disease control, overall survival of the participants between treatment arms, and the incidence of adverse and serious adverse events. TARGET included three investigational arms, vintafolide monotherapy and vintafolide in combination with docetaxel, each of which was compared to a standard-of-care control arm, docetaxel monotherapy..

About Vintafolide and Etarfolatide

Vintafolide is an investigational conjugate of folic acid (vitamin B9) linked to an anti-cancer agent, the potent vinca alkaloid desacetylvinblastine hydrazide (DAVLBH). Since cancer cells generally consume higher levels of folate than normal cells to fuel their growth, some cancer cell types – including NSCLC – have high concentrations of the folate receptor on their surface. Vintafolide is designed to selectively target the folate receptor to deliver the anti-cancer agent to the cancerous tissue. Tumors that have high concentrations of the folate receptor are identified by etarfolatide, a non-invasive imaging diagnostic agent.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com .

Endocyte Forward-Looking Statement

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's expectations for final clinical trial results and the initiation of future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the final overall survival analysis may be materially different than those referenced here, trials of earlier stage agents may not be successful or may take longer to complete than anticipated, and projected cash needs and expected financial results may be different. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 255

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 69

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 136

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 131

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 148

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 140

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 63

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Insights from OncoHost in Lung Cancer Treatment Strategy

Updated Category News Views 149

New Advances in Understanding Lung Cancer Treatment Resistance Recent findings from OncoHost shed light on the mechanisms behind resistance to immunotherapy in patients battling lung cancer. The study presents vital insights aimed at improving therapeutic strategies through advanced plasma proteomics analysis. Insights from Advanced Plasma Proteomics OncoHost, a...

Continue Reading
Understanding Eldorado Gold's Current Market Position and P/E

Updated Category News Views 167

Analyzing Eldorado Gold Inc's Current Market Situation At present, Eldorado Gold Inc. (NYSE: EGO) shares trade at a price of $27.34, reflecting a decrease of 5.85% in the current session. This decline comes after a slight drop of 1.19% over the past month. Despite this short-term volatility, when looking over a longer timeline, the stock shows impressive growth, having...

Continue Reading
Truecaller Achieves Remarkable Growth with 450 Million Users

Updated Category News Views 218

Truecaller Reaches 450 Million Monthly Active Users Truecaller, the renowned platform dedicated to verifying contacts and blocking unwanted communications, has reached a significant milestone, surpassing 450 million active users. This achievement marks another step in its impressive growth trajectory over the last year, with around 50 million new users added in just ten...

Continue Reading
Shell plc's Recent Share Buybacks: Key Insights Revealed

Updated Category News Views 377

Overview of Shell plc's Share Buyback Activities Shell plc has recently initiated significant share buyback activities as part of its ongoing strategy to enhance shareholder value. This move demonstrates the company's commitment to investing back into itself and optimizing capital allocation. The buybacks reflect Shell's strong financial position and positive outlook on...

Continue Reading
Wyndham Hotels Investigation: Uncovering Potential $50 Million Loss

Updated Category News Views 324

Investigation into Wyndham Hotels Sparks Concern Recent findings from internal records of Wyndham Hotels & Resorts have revealed alarming information suggesting that the Royalton Letter of Credit (LOC) was fully funded but not released. This situation raises troubling questions about potential securities and franchise-law violations involving multiple parties....

Continue Reading